These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 10881250)

  • 21. Metrifonate treatment of AD: influence of APOE genotype.
    Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
    Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes of galantamine treatment in patients with Alzheimer disease.
    Lyketsos CG; Reichman WE; Kershaw P; Zhu Y
    Am J Geriatr Psychiatry; 2004; 12(5):473-82. PubMed ID: 15353385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
    Bullock R; Erkinjuntti T; Lilienfeld S;
    Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Kurz AF; Erkinjuntti T; Small GW; Lilienfeld S; Damaraju CR
    Eur J Neurol; 2003 Nov; 10(6):633-40. PubMed ID: 14641507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
    Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.
    Pirttilä T; Wilcock G; Truyen L; Damaraju CV
    Eur J Neurol; 2004 Nov; 11(11):734-41. PubMed ID: 15525294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
    Wilcock GK; Lilienfeld S; Gaens E
    BMJ; 2000 Dec; 321(7274):1445-9. PubMed ID: 11110737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A naturalistic study of galantamine for Alzheimer's disease.
    Brodaty H; Woodward M; Boundy K; Barnes N; Allen G;
    CNS Drugs; 2006; 20(11):935-43. PubMed ID: 17044730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
    Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
    J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
    Thavichachart N; Phanthumchinda K; Chankrachang S; Praditsuwan R; Nidhinandana S; Senanarong V; Poungvarin N
    Int J Clin Pract; 2006 May; 60(5):533-40. PubMed ID: 16700849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galantamine: additional benefits to patients with Alzheimer's disease.
    Lilienfeld S; Parys W
    Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():19-27. PubMed ID: 10971048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.
    Wilkinson D; Murray J
    Int J Geriatr Psychiatry; 2001 Sep; 16(9):852-7. PubMed ID: 11571763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
    Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
    Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
    Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
    Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
    Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
    Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
    Tariot PN
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S26-33. PubMed ID: 11669506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.